Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Organogenesis Holdings Inc. (AHPA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance CANTON, Mass., -- Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023. Second Quarter 2023 Financial Results Summary: • Net revenue of $117.3 million for the second quarter of 2023, a decrease of $4.1 million compared to net revenue of $121.4 million for the second quarter of 2022. Net revenue for the second quarter of 2023 consists of: o Net revenue from Advanced Wound Care products of $110.1 million, a decrease of 3% from the se..."
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results CANTON, Mass., -- Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Summary: • Net revenue of $107.6 million for the first quarter of 2023, an increase of $10.5 million compared to net revenue of $97.1 million for the first quarter of 2022. Net revenue for the first quarter of 2023 consists of: o Net revenue from Advanced Wound Care products of $100.9 million, an increase of 12% from the first quarter of 2022. o Net revenue from S..."
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/06/2023 SC 13G/A BlackRock Inc. reports a 3.4% stake in Organogenesis Holdings Inc.
04/04/2023 4 Grow Brian (Chief Commercial Officer) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Paid exercise price by delivering 2,408 shares @ $2.13, valued at $5.1k
04/04/2023 4 Montecalvo Antonio S. (Vice President, Health Policy) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Paid exercise price by delivering 2,097 shares @ $2.13, valued at $4.5k
04/04/2023 4 Gillheeney Gary S. (President and CEO) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Paid exercise price by delivering 6,470 shares @ $2.13, valued at $13.8k
04/04/2023 4 Freedman Lori (Chief Admin. and Legal Officer) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Paid exercise price by delivering 2,339 shares @ $2.13, valued at $5k
04/04/2023 4 Bilbo Patrick (COO) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Paid exercise price by delivering 2,678 shares @ $2.13, valued at $5.7k
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K Quarterly results
Docs: "Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance CANTON, Mass., -- Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022. Fourth Quarter 2022 Financial Results Summary: • Net revenue of $115.5 million for the fourth quarter of 2022, a decrease of 10% compared to net revenue of $127.9 million for the fourth quarter of 2021. Net revenue for the fourth quarter of 2022 consists of: o Net revenue from Advanced Wound Care products of $108.8 million, a..."
02/24/2023 4 Montecalvo Antonio S. (Vice President, Health Policy) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 99,428 shares @ $0
Granted 118,035 options to buy @ $2.51, valued at $296.3k
02/24/2023 4 Freedman Lori (VP and General Counsel) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 278,884 shares @ $0
Granted 331,076 options to buy @ $2.51, valued at $831k
02/24/2023 4 Grow Brian (Chief Commercial Officer) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 291,009 shares @ $0
Granted 345,470 options to buy @ $2.51, valued at $867.1k
02/24/2023 4 Bilbo Patrick (COO) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 327,386 shares @ $0
Granted 388,654 options to buy @ $2.51, valued at $975.5k
02/24/2023 4 Francisco David (CFO) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 242,508 shares @ $0
Granted 287,892 options to buy @ $2.51, valued at $722.6k
02/24/2023 4 Gillheeney Gary S. (President and CEO) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 896,414 shares @ $0
Granted 1,655,381 options to buy @ $2.51, valued at $4.2M
02/24/2023 4 Duraibabu Prathyusha (Director) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 65,737 shares @ $0
02/24/2023 4 Quintero Gilberto (Director) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 65,737 shares @ $0
02/24/2023 4 Korfin Michele Ilene (Director) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 65,737 shares @ $0
02/24/2023 4 Driscoll Michael Joseph (Director) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 65,737 shares @ $0
02/24/2023 4 Giacomin Jon L (Director) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 65,737 shares @ $0
02/24/2023 4 Leibowitz Arthur S (Director) has filed a Form 4 on Organogenesis Holdings Inc.
Txns: Granted 65,737 shares @ $0
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Flynn James E reports a 0% stake in Organogenesis Holdings Inc.
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/09/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/22/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy